Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast

Biotechnology Journal

Volumn 1, Issue 3, 2006, Pages 282-288

  Vottero, Eduardo ^a   Balgi, Aruna ^a   Woods, Kate ^a   Tugendreich, Stuart ^b   Melese, Teri ^c   Andersen, Raymond J ^a   Mauk, A Grant ^a   Roberge, Michel ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ROSETTA INPHARMATICS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Drug screening; Indoleamine 2,3 dioxygenase; Inhibitor

Indexed keywords

ACTIVE COMPOUNDS; ALGAL EXTRACTS; CANCER; CHEMICAL BIOLOGY; DIAMIDES; DRUG DEVELOPMENT; DRUG SCREENING; DRUG TARGETS; HUMAN TUMORS; IMMUNE DETECTION; INDOLEAMINE 2 ,3-DIOXYGENASE; INHIBITOR; NATURAL EXTRACTS; PURE CHEMICALS; YEAST GROWTH;

AMINO ACIDS; DEGRADATION; LEAD COMPOUNDS; RESTORATION;

YEAST;

ENZYME INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; RECOMBINANT PROTEIN;

ARTICLE; BIOASSAY; CELL PROLIFERATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; METHODOLOGY; PHYSIOLOGY; SACCHAROMYCES CEREVISIAE;

BIOLOGICAL ASSAY; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE;

EID: 33645991772     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.200600001     Document Type: Article

References (30)

1. Muller, A.J., Malachowski, W.P., Prendergast, G.C., Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin. Ther. Targets 2005, 9, 831-849.
2. Takikawa, O., Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem. Biophys. Res. Commun. 2005, 338, 12-19.
3. Grohmann, U., Fallarino, F., Puccetti, P., Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 2003, 24, 242-248.
4. Munn, D.H., Shafizadeh, E., Attwood, J.T., Bondarev, I., et al., Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999, 189, 1363-1372.
5. Hwu, P., Du, M.X., Lapointe, R., Do, M. et al., Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 2000, 164, 3596-3599.
6. Munn, D.H., Sharma, M.D., Lee, J.R., Jhaver, K.G. et al., Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297, 1867-1870.
7. Terness, P., Bauer, T.M., Rose, L., Dufter, C. et al., Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-express-ing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 2002, 196, 447-457.
8. Frumento, G., Rotondo, R., Tonetti, M., Damonte, G. et al., Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 2002, 196, 459-468.
9. Munn, D.H., Zhou, M., Attwood, J.T., Bondarev, I. et al., Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281, 1191-1193.
10. Uyttenhove, C., Pilotte, L., Theate, I., Stroobant, V. et al., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9, 1269-1274.
11. Munn, D.H., Sharma, M.D., Hou, D., Baban, B. et al., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 2004, 114, 280-290.
12. Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S. et al., Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 2005, 11, 6030-6039.
13. Takikawa, O., Littlejohn, T., Jamie, J.F., Walker, M.J., Truscott, R.J., Regulation of indoleamine 2,3-dioxygenase, the first enzyme in UV filter biosynthesis in the human lens. Relevance for senile nuclear cataract. Adv. Exp. Med. Biol. 1999, 467, 241-245.
14. Takikawa, O., Truscott, R.J., Fukao, M., Miwa, S., Age-related nuclear cataract and indoleamine 2,3-dioxygenase-initiated tryptophan metabolism in the human lens. Adv. Exp. Med. Biol. 2003, 527, 277-285.
15. Wichers, M.C., Maes, M., The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J. Psychiatry Neurosci. 2004, 29, 11-17.
16. Myint, A.M., Kim, Y.K., Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses 2003, 61, 519-525.
17. Muller, A.J., DuHadaway, J.B., Donover, P.S., Sutanto-Ward, E., Prendergast, G.C., Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 2005, 11, 312-319.
18. Mager, W.H., Winderickx, J., Yeast as a model for medical and medicinal research. Trends Pharmacol. Sci. 2005, 26, 265-273.
19. Melese, T., Hieter, P., From genetics and genomics to drug discovery: yeast rises to the challenge. Trends Pharmacol. Sci. 2002, 23, 544-547.
20. Simon, J.A., Bedalov, A., Yeast as a model system for anticancer drug discovery. Nat. Rev. Cancer 2004, 4, 481-492.
21. Tribouillard, D., Bach, S., Gug, F., Desban, N. et al., Using budding yeast to screen for anti-prion drugs. Biotechnol. J. 2006, 1, 58-67.
22. Tugendreich, S., Perkins, E., Couto, J., Barthmaier, P. et al., A streamlined process to phenotypically profile heterologous cDNAs in parallel using yeast cell-based assays. Genome Res. 2001, 11, 1899-1912.
23. Montalibet, J., Kennedy, B.P., Using yeast to screen for inhibitors of protein tyrosine phosphatase 1B. Biochem. Pharmacol. 2004, 68, 1807-1814.
24. Perkins, E., Sun, D., Nguyen, A., Tulac, S. et al., Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast. Cancer Res. 2001, 61, 4175-4183.
25. Kurtz, S., Luo, G., Hahnenberger, K.M., Brooks, C. et al., Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: identification of a novel inhibitor of influenza virus. Antimicrob. Agents Chemother. 1995, 39, 2204-2209.
26. Littlejohn, T.K., Takikawa, O., Truscott, R.J., Walker, M.J., Asp274 and his346 are essential for heme binding and catalytic function of human indoleamine 2,3-dioxygenase. J. Biol. Chem. 2003, 278, 29525-29531.
27. Holbeck, S.L., Update on NCI in vitro drug screen utilities. Eur. J. Cancer 2004, 40, 785-793.
28. Gaspari, P., Banerjee, T., Malachowski, W.P., Muller, A.J. et al., Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J. Med. Chem. 2006, 49, 684-692.
29. Parvez, M., Ara, J., Sultana, V., Qasim, R., Ahmad, V.U., Caulerpin. Acta Crystallogr. C 2000, 56, E96-97.
30. Vidal, J.P., Laurent, D., Kabore, S.A., Rechencq, E. et al., Caulerpin, caulerpicin, Caulerpa scalpelliformis: comparative acute toxicity study. Bot. Mar. 1984, 27, 533-537.